Karyopharm Therapeutics | KPTI - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Abbott USD 1.74B 2.94M 2026-03
Amgen USD 541M 1000K 2026-06
AstraZeneca USD 1.55B 44K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Incyte USD 200.98M 1.03M 2026-06
J&J USD 2.41B 1.35M 2026-03
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
MacroGenics USD 63.56M 241K 2026-03
Merck USD 2.47B 4.93M 2026-03
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Novartis USD 1.9B 7.38M 2026-06
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 0 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Takeda JPY 1.58B 460K 2026-06
Tectonic Therapeutic USD 18.83M 92.19K 2026-03
TG Therapeutics USD 153.08M 2.23M 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Xencor USD 74.33M 265K 2026-06